Genetically engineered microbes could create miniature drug factories inside the gut. Do the benefits outweigh the risks?
In the shadow of coronavirus vaccine development, another vaccine was making solid progress.
By studying elite controllers—people who are able to arrest the progress of HIV without medication—researchers have found a promising new path.
The fledgling field of chronotherapy—timing drugs to a patient’s circadian rhythms—may yet come to the aid of those at risk from the virus.
Autoimmune diseases are on the rise. The hunt is on to find their causes—including bacteria that may trigger the body to pick a fight with itself.
A calmer brain can lead to a healthier body. Researchers are beginning to pinpoint just where those benefits are coming from.
A milestone vaccine will soon move forward in clinical trials. But does its target—the MAP bacterium—actually play a role in the condition?
Peter L. Slavin and Timothy G. Ferris discuss the promise of CAR T cell therapy for solid tumors.
Those who suffer from chronic fatigue syndrome often face years of doubt from their medical providers. But now the physical hallmarks of the disease are coming into focus.
New T cell therapies succeed with a narrow band of cancers. Can they be made to work for the rest of them, too?